{"nct_id":"NCT06568939","title":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-01-20","start_date_type":"ACTUAL","primary_completion_date":"2028-02","primary_completion_date_type":"ESTIMATED","completion_date":"2028-02","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["ABBV"]}